Arcus Biosciences (RCUS) Misses Q4 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $31 million versus the consensus estimate of $29.03 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Ennis (EBF) Reports In-Line Q1 EPS
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance